Poseida Therapeutics, Inc.

NasdaqGS:PSTX Voorraadrapport

Marktkapitalisatie: US$361.6m

Poseida Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Poseida Therapeutics heeft een totaal eigen vermogen van $87.2M en een totale schuld van $58.9M, wat de schuld-eigenvermogensverhouding op 67.5% brengt. De totale activa en totale passiva bedragen respectievelijk $293.6M en $206.4M.

Belangrijke informatie

67.5%

Verhouding schuld/eigen vermogen

US$58.91m

Schuld

Rente dekkingsration/a
ContantUS$230.85m
AandelenUS$87.21m
Totaal verplichtingenUS$206.37m
Totaal activaUS$293.58m

Recente financiële gezondheidsupdates

Recent updates

Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30%

Oct 19
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30%

Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement

Sep 30

Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024

Sep 09

Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop

Aug 28
Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop

Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

May 21
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%

Apr 09
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%

Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement

Mar 17

Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Jan 24
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too

Dec 18
Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too

New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Aug 13
New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding

Apr 17
Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding

Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech

Sep 04

Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M

Aug 11

Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B

Aug 03

Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

May 15
Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

Poseida Therapeutics: Genome Engineering For Safer Cell Therapies

Oct 30

What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Mar 19
What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?

Jan 25
Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?

Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Dec 09

FDA lifts clinical hold on Poseida's prostate cancer cell therapy study

Nov 02

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $250.7M ) PSTX } overtreffen de korte termijn passiva ( $78.3M ).

Langlopende schulden: De kortetermijnactiva PSTX ( $250.7M ) overtreffen de langetermijnschulden ( $128.1M ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: PSTX heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van PSTX is de afgelopen 5 jaar gestegen van 52.1% naar 67.5%.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: PSTX heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.

Voorspelling contante baan: PSTX heeft voldoende kasruimte voor 1.7 jaar als de vrije kasstroom blijft groeien met een historisch percentage van 10 % per jaar.


Ontdek gezonde bedrijven